Development of a new parallelized, optical biosensor platform for label-free detection of autoimmunity-related antibodies Multiplex Platforms in Diagnostics and Bioanalytics

Oliver Bleher; Aline Schindler; Meng Xin Yin; Andrew B. Holmes; Peter B. Luppa; Günter Gauglitz; Günther Proll

doi:10.1007/s00216-013-7504-y

Development of a new parallelized, optical biosensor platform for label-free detection of autoimmunity-related antibodies Multiplex Platforms in Diagnostics and Bioanalytics

Oliver Bleher, Aline Schindler, Meng Xin Yin, Andrew B. Holmes, Peter B. Luppa, Günter Gauglitz, Günther Proll

Default

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Autoimmune diseases are characterized by the presence of autoantibodies in serum of affected patients. The heterogeneity of autoimmune relevant antigens creates a variety of different antibodies, which requires a simultaneous detection mode. For this reason, we developed a tool for parallelized, label-free, optical detection that accomplishes the characterization of multiple antigen-antibody interactions within a single measurement on a timescale of minutes. Using 11-aminoundecyltrimethoxysilane, we were able to immobilize proteinogenic antigens as well as an amino-functionalized cardiolipin on a glass surface. Assay conditions were optimized for serum measurements with a single spot antigen chip on a single spot 1-λ detection system. Minimized background signal allows a differentiation between patients and healthy controls with a good sensitivity and specificity. Applying polarized imaging reflectometric interference spectroscopy, we evaluated samples from three APS patients and three control subjects for this proof-of-principle and already obtained good results for β2-glycoprotein I and cardiolipin.

Original language	English
Pages (from-to)	3305-3314
Number of pages	10
Journal	Analytical and Bioanalytical Chemistry
Volume	406
Issue number	14
DOIs	https://doi.org/10.1007/s00216-013-7504-y
State	Published - May 2014

Keywords

Antiphospholipid syndrome
Label-free detection
Microarray
Optical sensors
Reflectometric interference spectroscopy
β2-Glycoprotein I

Access to Document

10.1007/s00216-013-7504-y

Cite this

Bleher, O., Schindler, A., Yin, M. X., Holmes, A. B., Luppa, P. B., Gauglitz, G., & Proll, G. (2014). Development of a new parallelized, optical biosensor platform for label-free detection of autoimmunity-related antibodies Multiplex Platforms in Diagnostics and Bioanalytics. Analytical and Bioanalytical Chemistry, 406(14), 3305-3314. https://doi.org/10.1007/s00216-013-7504-y

@article{63e9dfb8f70e45a2b189d6a677c362ba,

title = "Development of a new parallelized, optical biosensor platform for label-free detection of autoimmunity-related antibodies Multiplex Platforms in Diagnostics and Bioanalytics",

abstract = "Autoimmune diseases are characterized by the presence of autoantibodies in serum of affected patients. The heterogeneity of autoimmune relevant antigens creates a variety of different antibodies, which requires a simultaneous detection mode. For this reason, we developed a tool for parallelized, label-free, optical detection that accomplishes the characterization of multiple antigen-antibody interactions within a single measurement on a timescale of minutes. Using 11-aminoundecyltrimethoxysilane, we were able to immobilize proteinogenic antigens as well as an amino-functionalized cardiolipin on a glass surface. Assay conditions were optimized for serum measurements with a single spot antigen chip on a single spot 1-λ detection system. Minimized background signal allows a differentiation between patients and healthy controls with a good sensitivity and specificity. Applying polarized imaging reflectometric interference spectroscopy, we evaluated samples from three APS patients and three control subjects for this proof-of-principle and already obtained good results for β2-glycoprotein I and cardiolipin.",

keywords = "Antiphospholipid syndrome, Label-free detection, Microarray, Optical sensors, Reflectometric interference spectroscopy, β2-Glycoprotein I",

author = "Oliver Bleher and Aline Schindler and Yin, {Meng Xin} and Holmes, {Andrew B.} and Luppa, {Peter B.} and G{\"u}nter Gauglitz and G{\"u}nther Proll",

note = "Funding Information: Acknowledgments We gratefully thank Dr. Peter Fechner from Biametrics GmbH for the design and fabrication of the PDMS flow cell and for providing it to us. We thank the Deutsche Forschungsgemeinschaft (DFG) for funding this project (project numbers PR1192/2-1 and LU 520/5-1).",

year = "2014",

month = may,

doi = "10.1007/s00216-013-7504-y",

language = "English",

volume = "406",

pages = "3305--3314",

journal = "Analytical and Bioanalytical Chemistry",

issn = "1618-2642",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "14",

}

Bleher, O, Schindler, A, Yin, MX, Holmes, AB, Luppa, PB, Gauglitz, G & Proll, G 2014, 'Development of a new parallelized, optical biosensor platform for label-free detection of autoimmunity-related antibodies Multiplex Platforms in Diagnostics and Bioanalytics', Analytical and Bioanalytical Chemistry, vol. 406, no. 14, pp. 3305-3314. https://doi.org/10.1007/s00216-013-7504-y

Development of a new parallelized, optical biosensor platform for label-free detection of autoimmunity-related antibodies Multiplex Platforms in Diagnostics and Bioanalytics. / Bleher, Oliver; Schindler, Aline; Yin, Meng Xin et al.
In: Analytical and Bioanalytical Chemistry, Vol. 406, No. 14, 05.2014, p. 3305-3314.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Development of a new parallelized, optical biosensor platform for label-free detection of autoimmunity-related antibodies Multiplex Platforms in Diagnostics and Bioanalytics

AU - Bleher, Oliver

AU - Schindler, Aline

AU - Yin, Meng Xin

AU - Holmes, Andrew B.

AU - Luppa, Peter B.

AU - Gauglitz, Günter

AU - Proll, Günther

N1 - Funding Information: Acknowledgments We gratefully thank Dr. Peter Fechner from Biametrics GmbH for the design and fabrication of the PDMS flow cell and for providing it to us. We thank the Deutsche Forschungsgemeinschaft (DFG) for funding this project (project numbers PR1192/2-1 and LU 520/5-1).

PY - 2014/5

Y1 - 2014/5

N2 - Autoimmune diseases are characterized by the presence of autoantibodies in serum of affected patients. The heterogeneity of autoimmune relevant antigens creates a variety of different antibodies, which requires a simultaneous detection mode. For this reason, we developed a tool for parallelized, label-free, optical detection that accomplishes the characterization of multiple antigen-antibody interactions within a single measurement on a timescale of minutes. Using 11-aminoundecyltrimethoxysilane, we were able to immobilize proteinogenic antigens as well as an amino-functionalized cardiolipin on a glass surface. Assay conditions were optimized for serum measurements with a single spot antigen chip on a single spot 1-λ detection system. Minimized background signal allows a differentiation between patients and healthy controls with a good sensitivity and specificity. Applying polarized imaging reflectometric interference spectroscopy, we evaluated samples from three APS patients and three control subjects for this proof-of-principle and already obtained good results for β2-glycoprotein I and cardiolipin.

AB - Autoimmune diseases are characterized by the presence of autoantibodies in serum of affected patients. The heterogeneity of autoimmune relevant antigens creates a variety of different antibodies, which requires a simultaneous detection mode. For this reason, we developed a tool for parallelized, label-free, optical detection that accomplishes the characterization of multiple antigen-antibody interactions within a single measurement on a timescale of minutes. Using 11-aminoundecyltrimethoxysilane, we were able to immobilize proteinogenic antigens as well as an amino-functionalized cardiolipin on a glass surface. Assay conditions were optimized for serum measurements with a single spot antigen chip on a single spot 1-λ detection system. Minimized background signal allows a differentiation between patients and healthy controls with a good sensitivity and specificity. Applying polarized imaging reflectometric interference spectroscopy, we evaluated samples from three APS patients and three control subjects for this proof-of-principle and already obtained good results for β2-glycoprotein I and cardiolipin.

KW - Antiphospholipid syndrome

KW - Label-free detection

KW - Microarray

KW - Optical sensors

KW - Reflectometric interference spectroscopy

KW - β2-Glycoprotein I

UR - http://www.scopus.com/inward/record.url?scp=84901600855&partnerID=8YFLogxK

U2 - 10.1007/s00216-013-7504-y

DO - 10.1007/s00216-013-7504-y

M3 - Article

C2 - 24281326

AN - SCOPUS:84901600855

SN - 1618-2642

VL - 406

SP - 3305

EP - 3314

JO - Analytical and Bioanalytical Chemistry

JF - Analytical and Bioanalytical Chemistry

IS - 14

ER -

Development of a new parallelized, optical biosensor platform for label-free detection of autoimmunity-related antibodies Multiplex Platforms in Diagnostics and Bioanalytics

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this